Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1992-06-26
1997-12-02
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514 19, 514 20, 540575, A61K 3155, C07D40300
Patent
active
056936362
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to novel bicyclic compounds which inhibit platelet aggregation, pharmaceutical compositions containing the compounds and methods of using the compounds.
BACKGROUND OF THE INVENTION
Platelet aggregation is believed to be mediated primarily through the fibrinogen receptor, or GPIIb-IIIa platelet receptor complex, which is a member of a family of adhesion receptors referred to as integrins. It has been found that frequently the natural ligands of integrin receptors are proteins which contain an Arg-Gly-Asp sequence. Von Willebrand factor and fibrinogen, which are considered to be natural ligands for the GPIIb-IIIa receptor, possess an Arg-Gly-Asp (RGD in single letter amino acid code) sequence in their primary structure. Functionally, these proteins are able to bind and crosslink GPIIb-IIIa receptors on adjacent platelets and thereby effect aggregation of platelets.
Fibronectin, vitronectin and thrombospondin are RGD-containing proteins which have also been demonstrated to bind to GPIIb-IIIa. Fibronectin is found in plasma and as a structural protein in the intracellular matrix. Binding between the structural proteins and GPIIb-IIIa may function to cause platelets to adhere to damaged vessel walls.
Linear and cyclic peptides which bind to vitronectin and contain an RGD sequence are disclosed in WO 89/05150 (PCT US88/04403). EP 0 275 748 discloses linear tetra- to hexapeptides and cyclic hexa- to octapeptides which bind to the GPIIb-IIIa receptor and inhibit platelet aggregation. Other linear and cyclic peptides, the disclosure of which are incorporated herein by reference, are reported in EP-A 0 341 915. However, the peptide like structures of such inhibitors often pose problems, such as in drug delivery, metabolic stability and selectivity. Inhibitors of the fibrinogen receptor which are not constructed of natural amino acid sequences are disclosed in EP-A 0 372,486, EP-A 0 381 033 and EP-A 0 478 363. WO 92/07568 (PCT/US91/08166) discloses fibrinogen receptor antagonists which mimic a conformational .gamma.-turn in the RGD sequence by forming a monocyclic seven-membered ring structure. There remains a need, however, for novel fibrinogen receptor antagonists (e.g. inhibitors of the GPIIb-IIIa protein) which have potent in vivo and in vitro effects and lack the peptide backbone structure of amino acid sequences.
The present invention discloses novel bicyclic compounds including benzazepines and benzodiazepines, which are inhibitors of the GPIIb-IIIa receptor and inhibit platelet aggregation. Certain 5-phenyl-1,4-benzodiazepines are known as a class of drugs which affect the central nervous system, and have been used as anxiolytics. See Sternbach, L. H., J. Med. Chem., 22, 2 (1979). It has also been disclosed that certain 5-phenyl-1,4-benzodiazepines antagonize the effects of cholecystokinin. See Friedinger, Med. Res. Rev., 9, 271 (1989). However, no such bicyclic compounds have been reported to have anti-platelet activity.
SUMMARY OF THE INVENTION
In one aspect this invention is a bicyclic compound comprising a substituted six-membered ring fused to a substituted seven-membered ring as described hereinafter in formula (I).
This invention is also a pharmaceutical composition for inhibiting platelet aggregation or clot formation, which comprises a compound of formula (I) and a pharmaceutically acceptable carrier.
This invention is further a method for inhibiting platelet aggregation in a mammal in need thereof, which comprises internally administering an effective amount of a compound of formula (I).
In another aspect, this invention provides a method for inhibiting reocclusion of an artery or vein in a mammal following fibrinolytic therapy, which comprises internally administering an effective amount of a fibrinolytic agent and a compound of formula (I). This invention is also a method for treating stroke, transient ischemia attacks, or myocardial infarction.
DETAILED DESCRIPTION OF THE INVENTION
This invention discloses novel bicyclic compounds which inhi
REFERENCES:
patent: 4297346 (1981-10-01), Rips
patent: 4322346 (1982-03-01), Korosi
patent: 4322436 (1982-03-01), Korosi et al.
patent: 4327026 (1982-04-01), Branca
patent: 4361511 (1982-11-01), Branca
patent: 4377522 (1983-03-01), Branca
patent: 4604389 (1986-08-01), Reiffen et al.
patent: 4737495 (1988-04-01), Bomhard et al.
patent: 4808713 (1989-02-01), Attwood et al.
patent: 4820834 (1989-04-01), Evans et al.
patent: 5008263 (1991-04-01), Cooper et al.
patent: 5017571 (1991-05-01), Hansen et al.
patent: 5059688 (1991-10-01), Effland et al.
patent: 5149699 (1992-09-01), Ellingboe et al.
patent: 5241065 (1993-08-01), Berger et al.
Sternbach, L.H., J. Med. Chem., 22, 2 (1979).
Friedinger, R.M., Cholecystokinin and Gastrin Antagonist, Med.Res.Rev., 9, 271 (1989).
Mori et al., New Synthesis of Diazepinone Skeleton Using Palladium Catalyzed Carbonylation, Heterocycles, 16 (1981).
Muller et al., Synthese von 1,2-annelierten 1, 4-Benzodiazepinen und 4, 1-Benzoxazepinen, Helv.Chim.Acta, 65, 2118 (1982).
Heindel et al., Synthesis, Transformation and General Pharmacologic Activity in 1,4-Benzodiazepine-3,5-diones, J.Med.Chem., 14, 1233 (1971).
Pauwells et al, Potent and Selective Inihibition of HIV-1 Replication in vitro by a Novel Series of TIBO Derivatives, Nature, 343, 470 (1990).
Nichols et al., J.Pharm.Exp.Ther., 270, 614 (1994).
Coller, Coronary Artery Disease, 3, 1016 (1992).
Topol et al, Thrombosis and Haemostasis, 70,94 (1993).
Nichols et al, TIPS, 13,413 (Nov. 1992).
Tighneanu et al, Double Cyclisation of Phenylglycine-o-carboxylic Acids-I, Tetrahedron, 36, 1385 (1980).
Callahan et al, Peptide Chemistry 1992: Proceedings of the 2nd Japanese Symposium on Peptides Chemistry, p. 495 (1993).
Ku et al, J.Am.Chem.Soc, 115, 8861 (1993).
Bondinell William Edward
Callahan James Francis
Huffman William Francis
Keenan Richard McCulloch
Ku Thomas Wen-Fu
Kinzig Charles M.
Lentz Edward T.
Shah Mukund J.
SmithKline Beecham Corporation
Sripada P. K.
LandOfFree
Bicyclic fibrinogen antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic fibrinogen antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic fibrinogen antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-801425